In this regard, Hinterleitner and colleagues reported that NSCLC tumor cells themselves would transfer PD-L1 to platelets and that PD-L1 from platelets with high CD62P levels can also distinguish a subgroup of patients with shorter survival following ICI treatment [43]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.